2-(2-Hydroxyethyl)-6-(4-(1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2-Hydroxyethyl)-6-(4-(1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone
• 英文别名: 2-(2-hydroxyethyl)-6-(4-imidazol-1-ylphenyl)pyridazin-3-one
• 化学式: C₁₅H₁₄N₄O₂
• 分子量: 282.3
• InChiKey: AAVUSVRIMQSDMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-2-methyl-3-(2H)-pyridazinone 、 4,5-dihydro-2(2-hydroxyethyl)-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone 、 溴 以 溶剂黄146 为溶剂， 以gives 2-methyl-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone and 2-[2-hydroxyethyl]-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone respectively的产率得到2-methyl-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone
  参考文献：
  名称：

  Substituted

  摘要：

  替代的4,5-二氢-6-[4-(1H-咪唑-1-基)-苯基]-3(2H)-吡啶嗪化合物和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪化合物及其药学上可接受的盐可作为心脏强心剂。该化合物能够使麻醉犬的心肌收缩力显著增强。该化合物通过将取代的γ-酮基苯丁酸与适当取代的肼反应制得4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪，然后脱氢得到6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪。中间体4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪化合物都可作为心脏强心剂。

  公开号：

  US04353905A1

文献信息

• Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0075436A1

  公开（公告）日：1983-03-30

  Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted y-oxobenzene-butanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and the 6-(substituted)-phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents. The compounds have the formula: where represents a double or single bond and A is anyone of five types of heterocyclic ring-containing radicals, and R2, R3 and Y are hydrogen or various substituents.

  取代的 4,5-二氢-6-(取代)苯基-3(2H)-哒嗪酮化合物和 6-(取代)苯基-3(2H)-哒嗪酮化合物及其药学上可接受的盐类可用作强心剂和降压药。 上述化合物可显著增强狗的心肌收缩力。所述化合物还能降低自发性高血压大鼠的血压。所述化合物是通过取代的 y-氧代苯丁酸与适当取代的肼反应生成 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮，后者脱氢生成 6-（取代）苯基-3(2H)-哒嗪酮。 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮和 6-（取代）苯基-3(2H)-哒嗪酮均可用作强心剂和降压药。这些化合物的化学式如下 其中代表双键或单键，A 是五种含杂环基中的任何一种，R2、R3 和 Y 是氢或各种取代基。
• US4353905A
  申请人：——

  公开号：US4353905A

  公开（公告）日：1982-10-12
• Substituted
  申请人：Warner-Lambert Company

  公开号：US04353905A1

  公开（公告）日：1982-10-12

  Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3(2H)-pyridazinone compounds and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted .gamma.-oxo-benzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones which are dehydrogenated to 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and the 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones are useful as cardiotonic agents.

  替代的4,5-二氢-6-[4-(1H-咪唑-1-基)-苯基]-3(2H)-吡啶嗪化合物和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪化合物及其药学上可接受的盐可作为心脏强心剂。该化合物能够使麻醉犬的心肌收缩力显著增强。该化合物通过将取代的γ-酮基苯丁酸与适当取代的肼反应制得4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪，然后脱氢得到6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪。中间体4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶嗪化合物都可作为心脏强心剂。